title: Reply to S. Barni et Al, K.R. Dearing et al, and N. Murray.
authors.affiliation: Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, Seville, Spain.
authors.forename: Luis G
authors.initials: LG
authors.lastname: Paz-Ares
authors.forename: Filippo
authors.initials: F
authors.lastname: de Marinis
authors.forename: Carla
authors.initials: C
authors.lastname: Visseren-Grul
authors.forename: Cesare
authors.initials: C
authors.lastname: Gridelli
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D005971:Glutamates / Q000627:therapeutic use*; D006147:Guanine / Q000031:analogs & derivatives*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
chemical_list: D000964:Antimetabolites, Antineoplastic; D005971:Glutamates; D006147:Guanine